Luye Pharma Group Ltd (LUP) - Net Assets

Latest as of December 2025: €18.36 Billion EUR ≈ $21.46 Billion USD

Based on the latest financial reports, Luye Pharma Group Ltd (LUP) has net assets worth €18.36 Billion EUR (≈ $21.46 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€32.83 Billion ≈ $38.38 Billion USD) and total liabilities (€14.47 Billion ≈ $16.91 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LUP intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets €18.36 Billion
% of Total Assets 55.93%
Annual Growth Rate 12.11%
5-Year Change 101.44%
10-Year Change N/A
Growth Volatility 10.44

Luye Pharma Group Ltd - Net Assets Trend (2016–2025)

This chart illustrates how Luye Pharma Group Ltd's net assets have evolved over time, based on quarterly financial data. See Luye Pharma Group Ltd (LUP) defensive interval to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Luye Pharma Group Ltd (2016–2025)

The table below shows the annual net assets of Luye Pharma Group Ltd from 2016 to 2025. For live valuation and market cap data, see Luye Pharma Group Ltd (LUP) market capitalisation.

Year Net Assets Change
2025-12-31 €18.36 Billion
≈ $21.46 Billion		 +16.54%
2024-12-31 €15.75 Billion
≈ $18.42 Billion		 +16.45%
2023-12-31 €13.53 Billion
≈ $15.82 Billion		 +22.52%
2022-12-31 €11.04 Billion
≈ $12.91 Billion		 +21.15%
2021-12-31 €9.11 Billion
≈ $10.66 Billion		 +12.53%
2020-12-31 €8.10 Billion
≈ $9.47 Billion		 -13.58%
2019-12-31 €9.37 Billion
≈ $10.96 Billion		 +18.12%
2018-12-31 €7.93 Billion
≈ $9.28 Billion		 +15.05%
2017-12-31 €6.90 Billion
≈ $8.06 Billion		 +5.09%
2016-12-31 €6.56 Billion
≈ $7.67 Billion		 --

Equity Component Analysis

This analysis shows how different components contribute to Luye Pharma Group Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Other Components €16.07 Billion 100.00%
Total Equity €16.07 Billion 100.00%

Luye Pharma Group Ltd Competitors by Market Cap

The table below lists competitors of Luye Pharma Group Ltd ranked by their market capitalization.

Company Market Cap
Shenzhen Liande Automatic Equipment Co Ltd
SHE:300545
 $1.02 Billion
TravelSky Technology Limited
F:TVL
 $1.02 Billion
Shenzhen Minkave Technology Co Ltd
SHE:300506
 $1.02 Billion
Inrom Construction Industries Ltd
TA:INRM
 $1.02 Billion
Shanghai Diesel Engine Co Ltd A
SHG:600841
 $1.02 Billion
Ji'an Mankun Technology Co. Ltd. A
SHE:301132
 $1.02 Billion
Inversiones Aguas Metropolitanas SA
SN:IAM
 $1.02 Billion
Nobia AB
ST:NOBI
 $1.02 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Luye Pharma Group Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 14,154,529,000 to 16,072,554,000, a change of 1,918,025,000 (13.6%).
  • Net income of 618,747,000 contributed positively to equity growth.
  • New share issuances of 1,038,379,000 increased equity.
  • Other factors increased equity by 260,899,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €618.75 Million +3.85%
Share Issuances €1.04 Billion +6.46%
Other Changes €260.90 Million +1.62%
Total Change €- 13.55%

Book Value vs Market Value Analysis

This analysis compares Luye Pharma Group Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.05x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 €2.11 €0.22 x
2018-12-31 €2.38 €0.22 x
2019-12-31 €2.92 €0.22 x
2020-12-31 €2.52 €0.22 x
2021-12-31 €2.40 €0.22 x
2022-12-31 €2.96 €0.22 x
2023-12-31 €3.33 €0.22 x
2024-12-31 €3.76 €0.22 x
2025-12-31 €4.02 €0.22 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Luye Pharma Group Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 3.85%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 9.81%
  • • Asset Turnover: 0.19x
  • • Equity Multiplier: 2.04x
  • Recent ROE (3.85%) is below the historical average (8.57%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 13.87% 30.56% 0.32x 1.43x €248.68 Million
2017 14.50% 25.73% 0.35x 1.59x €304.53 Million
2018 16.69% 25.19% 0.29x 2.25x €522.53 Million
2019 15.92% 23.10% 0.33x 2.09x €546.15 Million
2020 8.95% 12.76% 0.27x 2.61x €-82.54 Million
2021 -1.58% -2.58% 0.23x 2.66x €-983.20 Million
2022 5.94% 10.11% 0.25x 2.38x €-412.79 Million
2023 4.25% 8.67% 0.24x 2.03x €-720.51 Million
2024 3.33% 7.79% 0.20x 2.09x €-943.57 Million
2025 3.85% 9.81% 0.19x 2.04x €-988.51 Million

Industry Comparison

This section compares Luye Pharma Group Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $6,522,543,280
  • Average return on equity (ROE) among peers: -40.38%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Luye Pharma Group Ltd (LUP) €18.36 Billion 13.87% 0.79x $1.02 Billion
SHANG.FOS.PHARM.GR.H YC 1 (08HH) $61.84 Billion 5.45% 0.94x $1.12 Billion
PEPTONIC MEDICAL (28L) $53.12 Million -138.73% 0.59x $4.14 Million
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) $2.95 Billion 12.14% 0.85x $692.11 Million
WEST ISLAND BRANDS INC. (39N0) $3.27 Million -157.21% 0.88x $1.34 Million
AYURCANN HOLDINGS CORP. (3ZQ0) $4.89 Million -63.10% 0.49x $97.35K
CERENO SCIENTIFIC AB B (4A1) $191.93 Million -51.86% 1.16x $157.72 Million
MAPLE LEAF GREEN WORLD (4HV0) $-8.83 Million 0.00% 0.00x $504.30K
LORDS CO. WORLDW. HOLD. (4XM) $-1.01 Million 0.00% 0.00x $134.78K
RED LIGHT HOLLAND CORP. (4YX) $17.35 Million -23.30% 0.22x $7.31 Million
EQL PHARMA AB (7JK) $177.73 Million 12.78% 1.10x $78.20 Million

About Luye Pharma Group Ltd

F:LUP Germany Drug Manufacturers - Specialty & Generic
Market Cap
$1.02 Billion
€870.80 Million EUR
Market Cap Rank
#8996 Global
#1142 in Germany
Share Price
€0.22
Change (1 day)
+2.83%
52-Week Range
€0.19 - €0.48
All Time High
€0.70
Categories
Companies in Germany Drug Manufacturers - Specialty & Generic
About

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more